Cargando…

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report

BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovelli, Valentina, Zuvadelli, Juri, Piotto, Marta, Scopari, Andrea, Dionigi, Alice Re, Ercoli, Vittoria, Paci, Sabrina, Cefalo, Graziella, Salvatici, Elisabetta, Banderali, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962230/
https://www.ncbi.nlm.nih.gov/pubmed/35346323
http://dx.doi.org/10.1186/s13052-022-01249-y
_version_ 1784677752479154176
author Rovelli, Valentina
Zuvadelli, Juri
Piotto, Marta
Scopari, Andrea
Dionigi, Alice Re
Ercoli, Vittoria
Paci, Sabrina
Cefalo, Graziella
Salvatici, Elisabetta
Banderali, Giuseppe
author_facet Rovelli, Valentina
Zuvadelli, Juri
Piotto, Marta
Scopari, Andrea
Dionigi, Alice Re
Ercoli, Vittoria
Paci, Sabrina
Cefalo, Graziella
Salvatici, Elisabetta
Banderali, Giuseppe
author_sort Rovelli, Valentina
collection PubMed
description BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before, these have never been tried as co- treatments. L-alanine oral supplementation (LAOS) has been proven to reduce muscle breakdown: we hereby report the first case of supplementation on a PD patient on ERT. CASE PRESENTATION: F. is a 9 y.o. infantile onset Pompe Disease (IOPD) girl ERT-treated since age 1 developing a progressive myopathy. We started her on LAOS and performed assessments at baseline, 6 and 9 months. At baseline, F.’s weight, height and BMI were within normal ranges, while body composition showed low fat mass -FM and high resting energy expenditure—REE levels. After LAOS, a progressive FM increase and REE reduction could be observed both at 6 and 9 months. CONCLUSIONS: ERT is not curative for PD patients thus additional treatments could be considered to improve outcomes. Our patient showed physical signs of inability to accumulate energy when exclusively on ERT, while FM increase and REE reduction occurred when supplemented with LAOS, likely reflecting anabolic pathways’ implementation. This is the first case reporting potential LAOS benefits in PD-on ERT patients. Longitudinal case control studies are yet needed to evaluate possible efficacy of combined LAOS And ERT treatment in PD patients.
format Online
Article
Text
id pubmed-8962230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89622302022-03-30 L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report Rovelli, Valentina Zuvadelli, Juri Piotto, Marta Scopari, Andrea Dionigi, Alice Re Ercoli, Vittoria Paci, Sabrina Cefalo, Graziella Salvatici, Elisabetta Banderali, Giuseppe Ital J Pediatr Case Report BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before, these have never been tried as co- treatments. L-alanine oral supplementation (LAOS) has been proven to reduce muscle breakdown: we hereby report the first case of supplementation on a PD patient on ERT. CASE PRESENTATION: F. is a 9 y.o. infantile onset Pompe Disease (IOPD) girl ERT-treated since age 1 developing a progressive myopathy. We started her on LAOS and performed assessments at baseline, 6 and 9 months. At baseline, F.’s weight, height and BMI were within normal ranges, while body composition showed low fat mass -FM and high resting energy expenditure—REE levels. After LAOS, a progressive FM increase and REE reduction could be observed both at 6 and 9 months. CONCLUSIONS: ERT is not curative for PD patients thus additional treatments could be considered to improve outcomes. Our patient showed physical signs of inability to accumulate energy when exclusively on ERT, while FM increase and REE reduction occurred when supplemented with LAOS, likely reflecting anabolic pathways’ implementation. This is the first case reporting potential LAOS benefits in PD-on ERT patients. Longitudinal case control studies are yet needed to evaluate possible efficacy of combined LAOS And ERT treatment in PD patients. BioMed Central 2022-03-28 /pmc/articles/PMC8962230/ /pubmed/35346323 http://dx.doi.org/10.1186/s13052-022-01249-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Rovelli, Valentina
Zuvadelli, Juri
Piotto, Marta
Scopari, Andrea
Dionigi, Alice Re
Ercoli, Vittoria
Paci, Sabrina
Cefalo, Graziella
Salvatici, Elisabetta
Banderali, Giuseppe
L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title_full L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title_fullStr L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title_full_unstemmed L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title_short L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
title_sort l-alanine supplementation in pompe disease (iopd): a potential therapeutic implementation for patients on ert? a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962230/
https://www.ncbi.nlm.nih.gov/pubmed/35346323
http://dx.doi.org/10.1186/s13052-022-01249-y
work_keys_str_mv AT rovellivalentina lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT zuvadellijuri lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT piottomarta lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT scopariandrea lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT dionigialicere lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT ercolivittoria lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT pacisabrina lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT cefalograziella lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT salvaticielisabetta lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport
AT banderaligiuseppe lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport